NCT02072863 - A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

September 30, 2015

Conditions

Multiple Myeloma

Interventions

DRUG

Oprozomib

Study subjects will receive oprozomib administered orally.

DRUG

Melphalan

Study subjects will receive melphalan 9 mg/m2.

DRUG

Prednisone

Study subjects will receive prednisone 60 mg/m2.

Trial Locations (8)

Department of Clinical Therapeutics, University of Athens, Athens

Ospedale Oncologico Regionale, Rionero in Vulture

Azienda Ospedaliera Universitaria S Martino, Genova

AOU Maggiore della Carita, SCDU Heamatology, Novara

University of Rome, Rome

Hospital City of Health and Science of Turin, Hematology 1 Division, Turin

Vrijc Universiteit Medisch Centrum, Department of Hematology, Amsterdam

Erasmus MC, Department of Hematology, Rotterdam